A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.

被引：0
|
作者：
Ling, Huichung Tina
Muggia, Franco
Speyer, James L.
Curtin, John Patrick
Blank, Stephanie V.
Boyd, Leslie R.
Pothuri, Bhavana
Li, Xiaochun
Goldberg, Judith D.
Tiersten, Amy
机构：
[1] Permanente Med Grp Inc, Hayward, CA USA
[2] NYU, Sch Med, New York, NY USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5564
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
    Jain, Salvia Sanjay
    Makeyev, Yan G.
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Fishman, David
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
    Musa, Fernanda
    Pothuri, Bhavana
    Blank, Stephanie V.
    Ling, Huichung T.
    Speyer, James L.
    Curtin, John
    Boyd, Leslie
    Li, Xiaochun
    Goldberg, Judith D.
    Muggia, Franco
    Tiersten, Amy
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 279 - 284
  • [3] A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
    Liu, J. F.
    Herold, C.
    Luo, W.
    Penson, R.
    Horowitz, N.
    Konstantinopoulos, P.
    Castro, C.
    Curtis, J.
    Matulonis, U. A.
    Cannistra, S.
    Dizon, D. S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer.
    Burtness, B
    Sipples, R
    Mirto, G
    Thomas, L
    Ahman, ZA
    Kloss, RA
    Murren, J
    Lacy, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 342S - 342S
  • [5] Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Dowel, Jeannette M.
    Reardon, David A.
    Quinn, Jennifer A.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sridharan
    Wagner, Melissa
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1253 - 1259
  • [6] Delta tocotrienol in recurrent ovarian cancer. A phase II trial
    Thomsen, Caroline Brenner
    Andersen, Rikke Fredslund
    Steffensen, Karina Dahl
    Adimi, Parvin
    Jakobsen, Anders
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 141 : 392 - 396
  • [7] Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer
    Ghosh, Jaya
    Kumar, Lalit
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 7 - U37
  • [8] A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma
    Chinnaiyan, P.
    Chowdhary, S.
    Brem, S.
    Yu, M.
    Murtagh, R.
    Rojiani, A.
    Tsai, Y.
    Pan, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [10] A phase II trial of combination irinotecan and oral etoposide chemotherapy in recurrent ovarian cancer: A Tohoku Gynecologic Cancer Unit (TGCU) study
    Kumagai, S.
    Shoji, T.
    Yokoyama, Y.
    Takano, T.
    Mizunuma, H.
    Yaegashi, N.
    Sugiyama, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345